| Alemtuzumab-induced resolution of refractory cutaneous chronic graft-versus-host disease. | |
| | |
MedLine Citation:
|
PMID: 18158955 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
A patient with extensive cutaneous chronic graft-versus-host disease (cGVHD) affecting 100% of the body surface, with painful ulcerations that involved 20% of it, was treated unsuccessfully during 9 months with steroids, cyclosporine-A (CSa), sirolimus, tacrolimus, mychophenolate mofetil (MMF), infliximab, and rituximab. Twenty-one months after the allograft the patient was started on alemtuzumab, 10 mg/day subcutaneously, for 6 consecutive days every 4 weeks. Seven months after starting the treatment, 100% of the ulcers had disappeared, as had the pain. To our knowledge, there are no reports of the use of alemtuzumab in the treatment of extensive, ulcerated, refractory cutaneous cGVHD. The data presented here suggest that this agent may be useful in some patients with refractory forms of cGVHD. |
| | |
Authors:
|
Guillermo J Ruiz-Argüelles; Javier Gil-Beristain; Mario Magaña; Guillermo J Ruiz-Delgado |
Related Documents
:
|
6521615 - Steroid treatment lowers hepatic fibroplasia, as explored by serum aminoterminal procol... 9011365 - Topical steroid therapy in oral lichen planus: review of a novel delivery method in 24 ... 20172275 - Preliminary experience with alemtuzumab induction therapy combined with maintenance low... 18434855 - Long-term use of topical tacrolimus (fk506) in high-risk penetrating keratoplasty. 9848845 - The role of endoscopic third ventriculostomy in the management of shunt malfunction. 3369935 - Hemobilia. a disease in evolution. |
Publication Detail:
|
Type: Case Reports; Journal Article Date: 2007-12-03 |
Journal Detail:
|
Title: Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation Volume: 14 ISSN: 1523-6536 ISO Abbreviation: Biol. Blood Marrow Transplant. Publication Date: 2008 Jan |
Date Detail:
|
Created Date: 2007-12-26 Completed Date: 2008-01-22 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9600628 Medline TA: Biol Blood Marrow Transplant Country: United States |
Other Details:
|
Languages: eng Pagination: 7-9 Citation Subset: IM |
Affiliation:
|
Centro de Hematología y Medicina Interna de Puebla, Puebla, Mexico. gruiz1@clinicaruiz.com |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Antibodies, Monoclonal / therapeutic use* Antibodies, Neoplasm / therapeutic use* Chronic Disease / drug therapy Female Graft vs Host Disease / drug therapy*, pathology Hematopoietic Stem Cell Transplantation / adverse effects* Humans Leukemia, Myeloid, Acute / therapy Skin Ulcer / drug therapy*, pathology Transplantation, Homologous / adverse effects |
| Chemical | |
Reg. No./Substance:
|
0/Antibodies, Monoclonal; 0/Antibodies, Neoplasm; 0/alemtuzumab |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Anesthesia condition for (18)F-FDG imaging of lung metastasis tumors using small animal PET.
Next Document: Alemtuzumab for the treatment of steroid-refractory acute graft-versus-host disease.